When doctors first mentioned a "heart transplant," Grandmother Li instinctively recoiled: "A heart can be transplanted? Can I withstand such a risk?" It was the medical team, who repeatedly visited her bedside, explaining the surgical procedure in simple terms and dispelling fears with past successful cases. It was also the constant companionship and gentle encouragement from her family that finally gave her the courage to sign the transplant registration form solemnly.

Appendicitis does not always require surgical removal. For some patients, recovery can be achieved merely by relieving obstruction and controlling inflammation. The Department of Gastroenterology at Taikang Xianlin Drum Tower Hospital, Affiliated to Nanjing University Medical School, has recently adopted a new technique — Endoscopic Direct‑Vision Appendicitis Therapy (EDAT) — making appendix‑preserving and precise treatment achievable.

Recently, the Radiation Therapy Center of Hygeia Chang An Hospital Cancer Hospital has successfully implemented Spatially Fractionated Radiation Therapy (SFRT), benefiting multiple patients with complex tumors. For large‑volume, irregular, refractory recurrent tumors, tumors at special locations adjacent to vital organs and advanced‑stage cancers, this innovative technique can better destroy lesions while safeguarding critical organs.

Shanghai, July 6, 2026 — Jiahui International Cancer Center (JICC) announced that a 59-year-old male patient from New Zealand has successfully finished T-cell apheresis for Satricabtagene autoleucel (CT041). This marks the first international patient to complete T-cell collection in China for the world’s first approved solid tumor CAR-T therapy, demonstrating China’s global competitiveness in translational cell therapy and showcasing Chinese innovative treatments to global pa

Independently developed by Sichuan Biokin Pharmaceutical Co., Ltd., Izalontamab Brengitecan for Injection (Iza-Bren) is a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (bispecific ADC). It received its first NMPA approval in June 2026 for adult patients with recurrent/metastatic nasopharyngeal carcinoma who failed at least two lines of systemic chemotherapy plus PD-1/PD-L1 inhibitors, and previously obtained FDA Breakthrough Therapy Designation.

In traditional oncology, the "trial-and-error" method has long been a frustrating reality for patients. Clinicians prescribe standard chemotherapy and targeted regimens based on global guidelines.Today, a revolutionary technology known as Organoid Drug Sensitivity Testing is dismantling this paradigm. By cultivating a patient's micro-scale "biological avatar" in the laboratory, clinicians can pre-screen and predict the most effective drug combination before administration.

China’s first foreign patient treated with axicabtagene ciloleucel CAR-T therapy has been discharged from Shanghai Jiahui International Hospital. A Singaporean mother with refractory lymphoma chose Jiahui for its world-class care, shorter wait and lower cost vs Western countries. Supported by a full MDT team, she recovered smoothly, marking a milestone for China’s international CAR-T treatment.

Luxury polar cruise turns into a nightmare: a deadly virus with a 40% fatality rate spreads on board, causing multiple infections and deaths. The culprit is the Andes hantavirus, the only strain that can transmit human-to-human via respiratory droplets. Early symptoms resemble flu but quickly progress to fatal respiratory failure. The virus has a long incubation period and once triggered a super-spreading event in Argentina.

Recently, a team led by Chief Physician Chen Yicheng from the Department of Urology at Sir Run Run Shaw Hospital of Zhejiang University, together with a multidisciplinary team (MDT) including Nuclear Medicine, Medical Oncology, and Radiology, successfully administered Lutetium-177 Tixivapitide Injection (radioligand therapy) to a 70-something patient with prostate cancer.

The application of CAR-T cell therapy provides new treatment options for patients. Clinical evidence shows that CAR-T cell therapy has achieved remarkable efficacy in hematological malignancies, with some patients even achieving complete remission. All currently approved cellular products have reported these longterm durable responses. Studies show that 83% of lymphoma patients achieve remission after receiving CAR-T cell therapy, of whom 53% achieve complete remission [2].

With the continuous development of technologies such as artificial intelligence, multi-modal image fusion, and real-time dose monitoring, the CyberKnife of the future will have a higher level of intelligence. Its faster image processing speed, more accurate motion prediction models, and more adaptive treatment plan adjustments will allow this "radiation therapy drone" to cope freely on the anti-cancer battlefield, bringing patients safer, more efficient, and non-invasive new

"Currently, our team is capable of performing almost all the world’s most advanced cardiovascular interventional diagnosis and treatment technologies, striving to provide comprehensive treatment guarantees for patients with various high-risk, difficult, and complex cardiovascular diseases," said Fu Guosheng.

Minimally Invasive Cardiovascular Surgery (MICS) is one of the fastest-developing subspecialties in cardiovascular surgery. Due to less trauma, fewer complications, and faster recovery, MICS is a key development direction. The China National Minimally Invasive Cardiovascular Surgery Professional Committee (CMICS) promotes aligning domestic techniques with international standards. The goal is to summarize MICS progress in China, its clinical effects, and future trends.